Accumulation of amyloid-β (Aβ) in neurons accompanies Alzheimer’s disease progression. In the cytoplasm Aβ influences activity of proteasomes, the multisubunit protein complexes that hydrolyze the majority of intracellular proteins. However, the manner in which Aβ affects the proteolytic activity of proteasomes has not been established. In this study the effect of Aβ42 and Aβ42 with isomerized Asp7 on activity of different forms of proteasomes has been analyzed. It has been shown that Aβ peptides efficiently reduce activity of the 20S proteasomes, but increase activity of the 20S proteasomes capped with the 19S and/or 11S regulators. Modulation of proteasome activity is mainly determined by the C-terminal segment of Aβ (amino acids 17-42). This study demonstrated an important role of proteasome regulators in the interplay between Aβ and the proteasomes.
HardyJ, SelkoeDJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science297, 353–356.
2.
HaassC, SelkoeDJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol8, 101–112.
HongL, HuangHC, JiangZF (2014) Relationship between amyloid-beta and the ubiquitin-proteasome system in Alzheimer’s disease. Neurol Res36, 276–282.
7.
KellerJN, HanniKB, MarkesberyWR (2000) Impaired proteasome function in Alzheimer’s disease. J Neurochem75, 436–439.
8.
KeckS, NitschR, GruneT, UllrichO (2003) Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease. J Neurochem85, 115–122.
9.
de VrijFM, FischerDF, van LeeuwenFW, HolEM (2004) Protein quality control in Alzheimer’s disease by the ubiquitin proteasome system. Prog Neurobiol74, 249–270.
10.
TaiHC, Serrano-PozoA, HashimotoT, FroschMP, Spires-JonesTL, HymanBT (2012) The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol181, 1426–1435.
11.
JungT, GruneT (2013) The proteasome and the degradation of oxidized proteins: Part I-structure of proteasomes. Redox Biol1, 178–182.
12.
SchmidtM, FinleyD (2014) Regulation of proteasome activity in health and disease. Biochim Biophys Acta1843, 13–25.
13.
PickeringAM, DaviesKJ (2012) Degradation of damaged proteins: The main function of the 20S proteasome. Prog Mol Biol Transl Sci109, 227–248.
AlmeidaCG, TakahashiRH, GourasGK (2006) Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci26, 4277–4288.
22.
TsengBP, GreenKN, ChanJL, Blurton-JonesM, LaFerlaFM (2008) Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging29, 1607–1618.
23.
ZhaoX, YangJ (2010) Amyloid-beta peptide is a substrate of the human 20S proteasome. ACS Chem Neurosci1, 655–660.
24.
KristiansenM, DeriziotisP, DimcheffDE, JacksonGS, OvaaH, NaumannH, ClarkeAR, van LeeuwenFW, Menendez-BenitoV, DantumaNP, PortisJL, CollingeJ, TabriziSJ (2007) Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell26, 175–188.
25.
SchubertD, SoucekT, BlouwB (2009) The induction of HIF-1 reduces astrocyte activation by amyloid beta peptide. Eur J Neurosci29, 1323–1334.
DantumaNP, BottLC (2014) The ubiquitin-proteasome system in neurodegenerative diseases: Precipitating factor, yet part of the solution. Front Mol Neurosci7, 70.
28.
RenziehausenJ, HiebelC, NagelH, KunduA, KinsS, KogelD, BehlC, HajievaP (2015) The cleavage product of amyloid-beta protein precursor sAbetaPPalpha modulates BAG3-dependent aggresome formation and enhances cellular proteasomal activity. J Alzheimers Dis44, 879–896.
29.
GourasGK, TsaiJ, NaslundJ, VincentB, EdgarM, CheclerF, GreenfieldJP, HaroutunianV, BuxbaumJD, XuH, GreengardP, RelkinNR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol156, 15–20.
30.
MitkevichVA, PetrushankoIY, YegorovYE, SimonenkoOV, VishnyakovaKS, KulikovaAA, TsvetkovPO, MakarovAA, KozinSA (2013) Isomerization of Asp7 leads to increased toxic effect of amyloid-β42 on human neuronal cells. Cell Death Dis4, e939.
31.
KulikovaAA, CheglakovIB, KukharskyMS, OvchinnikovRK, KozinSA, MakarovAA (2016) Intracerebral injection of metal-binding domain of Abeta comprising the isomerized Asp7 increases the amyloid burden in transgenic mice. Neurotox Res29, 551–557.
RoherAE, PalmerKC, YurewiczEC, BallMJ, GreenbergBD (1993) Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem61, 1916–1926.
34.
ShimizuT, WatanabeA, OgawaraM, MoriH, ShirasawaT (2000) Isoaspartate formation and neurodegeneration in Alzheimer’s disease. Arch Biochem Biophys381, 225–234.
35.
IstrateAN, KozinSA, ZhokhovSS, MantsyzovAB, KechkoOI, PastoreA, MakarovAA, PolshakovVI (2016) Interplay of histidine residues of the Alzheimer’s disease Abeta peptide governs its Zn-induced oligomerization. Sci Rep6, 21734.
36.
TsvetkovPO, PopovIA, NikolaevEN, ArchakovAI, MakarovAA, KozinSA (2008) Isomerization of the Asp7 residue results in zinc-induced oligomerization of Alzheimer’s disease amyloid beta(1-16) peptide. Chembiochem9, 1564–1567.
37.
IndeykinaMI, PopovIA, KozinSA, KononikhinAS, KharybinON, TsvetkovPO, MakarovAA, NikolaevEN (2011) Capabilities of MS for analytical quantitative determination of the ratio of alpha- and betaAsp7 isoforms of the amyloid-beta peptide in binary mixtures. Anal Chem83, 3205–3210.
38.
KleinWL (2002) Aβ toxicity in Alzheimer’s disease: Globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int41, 345–352.
39.
MorozovVA, Il’inskiiPO, Il’inKV (1986) [Advantages and disadvantages of silver staining of proteins in polyacrylamide gel]. Biull Eksp Biol Med102, 620–623.
40.
AbramovaEB, AstakhovaTM, ErokhovPA, SharovaNP (2004) [Multiple forms of the proteasomes and some approaches to their separation]. Izv Akad Nauk Ser Biol150–156.
41.
OzakiM, FujinamiK, TanakaK, AmemiyaY, SatoT, OguraN, NakagawaH (1992) Purification and initial characterization of the proteasome from the higher plant Spinacia oleracea. J Biol Chem267, 21678–21684.
42.
KisselevAF, AkopianTN, WooKM, GoldbergAL (1999) The sizes of peptides generated from protein by mammalian 26 and 20S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem274, 3363–3371.
43.
ZirahS, KozinSA, MazurAK, BlondA, CheminantM, Segalas-MilazzoI, DebeyP, RebuffatS (2006) Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging. J Biol Chem281, 2151–2161.
44.
LuhrsT, RitterC, AdrianM, Riek-LoherD, BohrmannB, DobeliH, SchubertD, RiekR (2005) 3D structure of Alzheimer’s amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A102, 17342–17347.
45.
OsnaNA, WhiteRL, KrutikVM, WangT, WeinmanSA, DonohueTMJr (2008) Proteasome activation by hepatitis C core protein is reversed by ethanol-induced oxidative stress. Gastroenterology134, 2144–2152.
WaltersKJ, KleijnenMF, GohAM, WagnerG, HowleyPM (2002) Structural studies of the interaction between ubiquitin family proteins and proteasome subunit S5a. Biochemistry41, 1767–1777.
48.
QuerfurthHW, LaFerlaFM (2010) Alzheimer’s disease. N Engl J Med362, 329–344.
49.
FossatiS, ToddK, SotolongoK, GhisoJ, RostagnoA (2013) Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid beta and the Asn23 Iowa mutation. Biochem J456, 347–360.
50.
XinF, RadivojacP (2012) Post-translational modifications induce significant yet not extreme changes to protein structure. Bioinformatics28, 2905–2913.
51.
TomiyamaT, AsanoS, FuriyaY, ShirasawaT, EndoN, MoriH (1994) Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues. J Biol Chem269, 10205–10208.
LaiAY, McLaurinJ (2012) Inhibition of amyloid-beta peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease. Biochim Biophys Acta1822, 1629–1637.
60.
LinkCD, FonteV, HiesterB, YergJ, FergusonJ, CsontosS, SilvermanMA, SteinGH (2006) Conversion of green fluorescent protein into a toxic, aggregation-prone protein by C-terminal addition of a short peptide. J Biol Chem281, 1808–1816.
61.
ButterfieldDA (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer’s disease brain. A review. Free Radic Res36, 1307–1313.
62.
GruneT, CatalgolB, LichtA, ErmakG, PickeringAM, NgoJK, DaviesKJ (2011) HSP70 mediates dissociation and reassociation of the 26S proteasome during adaptation to oxidative stress. Free Radic Biol Med51, 1355–1364.
ReinheckelT, UllrichO, SitteN, GruneT (2000) Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress. Arch Biochem Biophys377, 65–68.
65.
TaiHC, SchumanEM (2008) Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci9, 826–838.
66.
PickeringAM, KoopAL, TeohCY, ErmakG, GruneT, DaviesKJ (2010) The immunoproteasome, the 20S proteasome and the PA28alphabeta proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochem J432, 585–594.
